[Research progress in pharmacological effects of Erigeron breviscapus and its active ingredients for treatment of Alzheimer's disease].

Abstract

Alzheimer's disease(AD) is a neurodegenerative disease that has no effective drug to cure it. Studies in several AD models have shown that Erigeron breviscapus and its active ingredients(scutellarin and caffeoylquinic acid) could improve/enhance the learning and memory ability, and the mechanisms are associated with inhibiting amyloid β(Aβ) production, aggregation, fibrosis and Aβ neurotoxicity toxicity, regulating cholinergic nervous system, inhibiting oxidative stress and inflammation, inhibiting tau hyperphosphorylation, improving mitochondrial function, and resisting neuronal apoptosis. This article systematically reviewed the research progress of E. breviscapus and its active ingredients for treatment of AD in AD models, in the expectation of providing references for further development of E. breviscapus's medicinal potential.

• Authors: Yuan-Zhu Pu, Can Su
• Journal: Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica (Zhongguo Zhong Yao Za Zhi) Vol. 45 Issue 23 Pg. 5650-5657 (Dec 2020) ISSN: 1001-5302 [Print] China
• PMID: 33496103 (Publication Type: Journal Article, Systematic Review)

Chemical References

• Amyloid beta-Peptides

Topics

• Alzheimer Disease
• Amyloid beta-Peptides
• Erigeron
• Humans
• Neurodegenerative Diseases